Pharmacogenetics and pharmacogenomics: a clinical reality

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 • 3,698 citations

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2003 • 3,532 citations

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

2009 • 3,433 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

2008 • 2,358 citations

HLA-B*5701 Screening for Hypersensitivity to Abacavir

2008 • 1,739 citations

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

2008 • 1,696 citations

A marker for Stevens–Johnson syndrome

2004 • 1,685 citations

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

2008 • 1,585 citations

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

2009 • 1,526 citations

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

2009 • 1,470 citations

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 • 1,432 citations

Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

2002 • 1,355 citations

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

2009 • 1,314 citations

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

2009 • 998 citations

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

2008 • 970 citations

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

2005 • 946 citations

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

2005 • 910 citations

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

2001 • 858 citations

Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

2003 • 829 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

2002 • 804 citations

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

2005 • 779 citations

Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study

1998 • 739 citations

Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

2007 • 731 citations

Clinical assessment incorporating a personal genome

2010 • 675 citations

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

2006 • 661 citations

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

2009 • 629 citations

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

2008 • 578 citations

The largest prospective warfarin-treated cohort supports genetic forecasting

2008 • 549 citations

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

2009 • 518 citations

Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese

2007 • 497 citations

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

2008 • 489 citations

Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population

2008 • 467 citations

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

2006 • 464 citations

Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

2004 • 444 citations

DRUG REACTIONS, ENZYMES, AND BIOCHEMICAL GENETICS

1957 • 437 citations

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

2008 • 423 citations

Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine

2001 • 403 citations

A marker for Stevens-Johnson syndrome …: ethnicity matters

2006 • 394 citations

CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study

2007 • 367 citations

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity

2005 • 360 citations

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

1996 • 321 citations

CYP2D6 and tamoxifen: DNA matters in breast cancer

2009 • 319 citations

Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer

2006 • 292 citations

Association of HLA-BFNx011502 allele and carbamazepine-inducedStevens-Johnson syndromeamong Indians

2009 • 291 citations

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

2004 • 290 citations

Enhanced proteolysis of thiopurine S -methyltransferase (TPMT) encoded by mutant alleles in humans ( TPMT ∗ 3 A , TPMT ∗ 2 ): Mechanisms for the genetic polymorphism of TPMT activity

1997 • 265 citations

HLA-B Locus in Caucasian Patients with Carbamazepine hypersensitivity

2006 • 261 citations

Genome-wide association studies in pharmacogenomics

2010 • 260 citations

Thiopurine methyltransferase activity in American white subjects and black subjects

1994 • 241 citations

Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer

2009 • 231 citations

Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia

1995 • 228 citations

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

2008 • 224 citations

Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer

2006 • 223 citations

Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel

1992 • 211 citations

Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population

2011 • 202 citations

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy

2008 • 189 citations

Gene-expression-based prognostic assays for breast cancer

2010 • 154 citations

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV

2008 • 150 citations

A genome-wide association study of acenocoumarol maintenance dosage

2009 • 145 citations

Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells

1999 • 119 citations

Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come

2010 • 116 citations

Drug hypersensitivity in HIV

2007 • 108 citations

Patients’ and Healthcare Professionals’ Views on Pharmacogenetic Testing and its Future Delivery in the NHS

2007 • 108 citations

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

2006 • 103 citations

Thiopurine Therapies

2005 • 102 citations

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

2010 • 87 citations

Clinical Pharmacogenomics of Thiopurine S-methyltransferase

2006 • 81 citations

Association of HLA-B*1502 allele and carbamazepine- induced severe adverse cutaneous drug reaction among Asians, a review

2008 • 73 citations

Deficient knowledge of genetics relevant for daily practice among medical students nearing graduation

2005 • 68 citations

Pharmacogenetics in Europe: Barriers and Opportunities

2009 • 61 citations

Pharmacogenomics, Evidence, and the Role of Payers

2009 • 61 citations

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain

2009 • 46 citations

New drug approval success rate in Europe in 2009

2010 • 41 citations

Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain

2010 • 34 citations

New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer

2007 • 31 citations

Removing Barriers to a Clinical Pharmacogenetics Service

2008 • 24 citations

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

2010 • 20 citations

Pharmacogenetic Testing in the United Kingdom Genetics and Immunogenetics Laboratories

2009 • 18 citations

The FDA announces new drug labeling for pharmacogenetic testing: Is personalized medicine becoming a reality?

2007 • 11 citations

Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development

2009 • 9 citations

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

2008 • 2 citations